Robot-assisted radical hysterectomy reduced mostly low-grade intraoperative complications vs open surgery in early-stage cervical cancer.
|Articles|March 1, 1999
- ONCOLOGY Vol 13 No 3
- Volume 13
- Issue 3
Commentary on Abstract #2479
Author(s)Bruce D. Cheson, MD
The bcl-2 gene is overexpressed in 80% to 90% of patients with follicular NHL. The product of this gene, the bcl-2 protein, not only protects cells from apoptosis but also induces a form of acquired resistance to a wide array of chemotherapy agents (Kitada et al: Blood 91:3379-3389, 1998).
Advertisement
The bcl-2 gene is overexpressed in 80% to 90% of patients with follicular NHL. The product of this gene, the bcl-2 protein, not only protects cells from apoptosis but also induces a form of acquired resistance to a wide array of chemotherapy agents (Kitada et al: Blood 91:3379-3389, 1998).
In vitro studies by Alas et al (abstract #2479) suggest that rituximab down-regulates bcl-2 expression and upregulates factors that induce cell-cycle arrest. These observations support the hypothesis that rituximab can sensitize lymphoma cells in vitro to chemotherapeutic agents. Such in vitro studies may provide the rationale for various antibody/chemotherapy combinations.
Articles in this issue
over 27 years ago
Navelbine Increased Elderly Lung Cancer Patients’ Survivalover 27 years ago
Consensus Statement on Prevention and Early Diagnosis of Lung CancerAdvertisement
Related to this article
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated round cell sarcomas in youth for pediatric patients.
Investigators of the phase 3 ACTION-1 trial will continue to follow up with patients to assess overall survival outcomes with RYZ101.
Ralph V. Boccia, MD, FACP, details remote monitoring, ICE scoring, CRS prophylaxis, and IVIG strategies for patients receiving bispecifics.
An expert panel discusses the case for de-escalating antibiotic therapy for pediatric patients who undergo hematopoietic cell transplantation.
Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Advertisement
Advertisement
Trending on CancerNetwork
1
Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization
2
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
3
Building a Low-Dose Radiation Therapy Program for Benign Disease
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5